English

ALEXION PHARMACEUTICALS, INC.

EDGAR

ALXN Quarterly report (10-Q) · filed 2021-04-30

225 filing records in this dataset, filed from 1996-06-13 to 2021-04-30. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

1.64 billion USD

2021 Q1 · USD

Exact inputs and evidence

Revenue: 1636500000 USD Source

Operating margin

38.88%

2021 Q1 · %

Exact inputs and evidence

Operating Income: 636200000 USD Source
Revenue: 1636500000 USD Source

Operating cash flow

638 million USD

2021 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: 637600000 USD Source

Free cash flow

617 million USD

2021 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: 637600000 USD Source
Capital Expenditure: 20200000 USD Source

Cash and cash equivalents: 3.43 billion USD 2021-03-31 Source
Exact value

3429600000 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

6.26 billion USD

2020-04-01 – 2021-03-31

Exact inputs and evidence

Revenue: 1444600000 USD · 2020-04-01 – 2020-06-30 Source
Revenue: 1588700000 USD · 2020-07-01 – 2020-09-30 Source
Revenue: 1591800000 USD · 2020-10-01 – 2020-12-31 Source
Revenue: 1636500000 USD · 2021-01-01 – 2021-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2021-04-30.

Financial data available through: 2020-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2020-12-31
Operating income: 11 of 11 periods available· newest 2020-12-31
Net income: 11 of 11 periods available· newest 2020-12-31
Operating cash flow: 11 of 11 periods available· newest 2020-12-31
Capital expenditure: 11 of 11 periods available· newest 2020-12-31
Total assets: 11 of 11 periods available· newest 2020-12-31
Total liabilities: 11 of 11 periods available· newest 2020-12-31
Current assets: 11 of 11 periods available· newest 2020-12-31
Current liabilities: 11 of 11 periods available· newest 2020-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2020-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+21.6%

Prior period

USD 4.99 billion

2019-01-01 – 2019-12-31
Current period

USD 6.07 billion

2020-01-01 – 2020-12-31

Exact inputs and evidence

6069900000 − 4991100000 = 1078800000 USD

4991100000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
6069900000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ALEXION PHARMACEUTICALS, INC. · 2020-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Year-over-year change in Revenue: 1078800000 USD Concept: fundies:Revenue Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 6069900000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2002474 Filing: 000089986621000014 Input fundies:Revenue: 4991100000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2003483 Filing: 000089986621000014
The citation records this snapshot. The page link may show a newer release later.
Net income
-74.9%

Prior period

USD 2.4 billion

2019-01-01 – 2019-12-31
Current period

USD 603.4 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

603400000 − 2404300000 = -1800900000 USD

2404300000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
603400000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ALEXION PHARMACEUTICALS, INC. · 2020-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Year-over-year change in Net income: -1800900000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 603400000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2617686 Filing: 000089986621000014 Input fundies:NetIncome: 2404300000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2618757 Filing: 000089986621000014
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+44%

Prior period

USD 2.08 billion

2019-01-01 – 2019-12-31
Current period

USD 3 billion

2020-01-01 – 2020-12-31

Exact inputs and evidence

3002900000 − 2084900000 = 918000000 USD

2084900000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
3002900000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ALEXION PHARMACEUTICALS, INC. · 2020-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Year-over-year change in Operating cash flow: 918000000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 3002900000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2310155 Filing: 000089986621000014 Input fundies:OperatingCashFlow: 2084900000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2311155 Filing: 000089986621000014
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-31%

Prior period

USD 154.7 million

2019-01-01 – 2019-12-31
Current period

USD 106.7 million

2020-01-01 – 2020-12-31

Exact inputs and evidence

106700000 − 154700000 = -48000000 USD

154700000 USD · 2019-01-01 – 2019-12-31
Inspect prior input Prior source
106700000 USD · 2020-01-01 – 2020-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ALEXION PHARMACEUTICALS, INC. · 2020-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Year-over-year change in Capital expenditure: -48000000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 106700000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2325852 Filing: 000089986621000014 Input fundies:CapitalExpenditure: 154700000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2326761 Filing: 000089986621000014
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2020 2020-01-01 – 2020-12-31

Revenue USD 6.07 billion 100% of revenue
Operating costs Derived USD 5.44 billion 90% of revenue
Operating income USD 632.3 million 10% of revenue
Tax, interest and other Derived USD 28.9 million 0.5% of revenue
Net income USD 603.4 million 9.9% of revenue

Cash

Operating cash flow USD 3 billion 49% of revenue
Capital expenditure USD 106.7 million 1.8% of revenue
Free cash flow Derived USD 2.9 billion 48% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2011 22%71%
2012 22%13%64%
2013 16%18%66%
2014 29%9.5%61%
2015 15%79%
2016 13%78%
2017 12%82%
2018 93%
2019 Net income was higher than operating income, so the split is not drawn.
2020 9.9%90%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2011 2011-01-01 – 2011-12-31	783431000	552605000 Derived	230826000	55511000 Derived	175315000	248102000 Derived	Source 2011-01-01 – 2011-12-31: 783431000 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: 230826000 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: 175315000 USD Inspect Net Income Open source 2011-01-01 – 2011-12-31: 270084000 USD Inspect Operating Cash Flow Open source 2011-01-01 – 2011-12-31: 21982000 USD Inspect Capital Expenditure Open source
2012 2012-01-01 – 2012-12-31	1134114000	729776000 Derived	404338000	149516000 Derived	254822000	388767000 Derived	Source 2012-01-01 – 2012-12-31: 1134114000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: 404338000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: 254822000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: 410613000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 21846000 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	1551346000	1023336000 Derived	528010000	275115000 Derived	252895000	468020000 Derived	Source 2013-01-01 – 2013-12-31: 1551346000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: 528010000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: 252895000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: 497349000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 29329000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	2234000000	1365000000 Derived	869000000	212000000 Derived	657000000	503000000 Derived	Source 2014-01-01 – 2014-12-31: 2234000000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: 869000000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: 657000000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: 640000000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 137000000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	2604000000	2067300000 Derived	536700000	392300000 Derived	144400000	388900000 Derived	Source 2015-01-01 – 2015-12-31: 2604000000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: 536700000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: 144400000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: 675200000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 286300000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	3084100000	2416700000 Derived	667400000	268000000 Derived	399400000	753600000 Derived	Source 2016-01-01 – 2016-12-31: 3084100000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: 667400000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: 399400000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 1086300000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 332700000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	3551100000	2923700000 Derived	627400000	184100000 Derived	443300000	758300000 Derived	Source 2017-01-01 – 2017-12-31: 3551100000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: 627400000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: 443300000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: 1115600000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 357300000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	4131200000	3861600000 Derived	269600000	192000000 Derived	77600000	213000000 Derived	Source 2018-01-01 – 2018-12-31: 4131200000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: 269600000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: 77600000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 426000000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 213000000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	4991100000	2870700000 Derived	2120400000	-283900000 Derived	2404300000	1930200000 Derived	Source 2019-01-01 – 2019-12-31: 4991100000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: 2120400000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: 2404300000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 2084900000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 154700000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	6069900000	5437600000 Derived	632300000	28900000 Derived	603400000	2896200000 Derived	Source 2020-01-01 – 2020-12-31: 6069900000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: 632300000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: 603400000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 3002900000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 106700000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 6.1B 2020

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20112011-12-31	Revenue	783431000	Revenue: 783431000 Open source
20122012-12-31	Revenue	1134114000	Revenue: 1134114000 Open source
20132013-12-31	Revenue	1551346000	Revenue: 1551346000 Open source
20142014-12-31	Revenue	2234000000	Revenue: 2234000000 Open source
20152015-12-31	Revenue	2604000000	Revenue: 2604000000 Open source
20162016-12-31	Revenue	3084100000	Revenue: 3084100000 Open source
20172017-12-31	Revenue	3551100000	Revenue: 3551100000 Open source
20182018-12-31	Revenue	4131200000	Revenue: 4131200000 Open source
20192019-12-31	Revenue	4991100000	Revenue: 4991100000 Open source
20202020-12-31	Revenue	6069900000	Revenue: 6069900000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

21.6% 2020

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Year over year	44.8%	Revenue: 783431000 Open source Revenue: 540957000 Open source
20122012-12-31	Year over year	44.8%	Revenue: 1134114000 Open source Revenue: 783431000 Open source
20132013-12-31	Year over year	36.8%	Revenue: 1551346000 Open source Revenue: 1134114000 Open source
20142014-12-31	Year over year	44%	Revenue: 2234000000 Open source Revenue: 1551346000 Open source
20152015-12-31	Year over year	16.6%	Revenue: 2604000000 Open source Revenue: 2234000000 Open source
20162016-12-31	Year over year	18.4%	Revenue: 3084100000 Open source Revenue: 2604000000 Open source
20172017-12-31	Year over year	15.1%	Revenue: 3551100000 Open source Revenue: 3084100000 Open source
20182018-12-31	Year over year	16.3%	Revenue: 4131200000 Open source Revenue: 3551100000 Open source
20192019-12-31	Year over year	20.8%	Revenue: 4991100000 Open source Revenue: 4131200000 Open source
20202020-12-31	Year over year	21.6%	Revenue: 6069900000 Open source Revenue: 4991100000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 10.4% 2020

Net margin 9.9% 2020

Free cash flow margin 47.7% 2020

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Operating margin	29.5%	Operating Income: 230826000 Open source Revenue: 783431000 Open source
20122012-12-31	Operating margin	35.7%	Operating Income: 404338000 Open source Revenue: 1134114000 Open source
20132013-12-31	Operating margin	34%	Operating Income: 528010000 Open source Revenue: 1551346000 Open source
20142014-12-31	Operating margin	38.9%	Operating Income: 869000000 Open source Revenue: 2234000000 Open source
20152015-12-31	Operating margin	20.6%	Operating Income: 536700000 Open source Revenue: 2604000000 Open source
20162016-12-31	Operating margin	21.6%	Operating Income: 667400000 Open source Revenue: 3084100000 Open source
20172017-12-31	Operating margin	17.7%	Operating Income: 627400000 Open source Revenue: 3551100000 Open source
20182018-12-31	Operating margin	6.5%	Operating Income: 269600000 Open source Revenue: 4131200000 Open source
20192019-12-31	Operating margin	42.5%	Operating Income: 2120400000 Open source Revenue: 4991100000 Open source
20202020-12-31	Operating margin	10.4%	Operating Income: 632300000 Open source Revenue: 6069900000 Open source
20112011-12-31	Net margin	22.4%	Net Income: 175315000 Open source Revenue: 783431000 Open source
20122012-12-31	Net margin	22.5%	Net Income: 254822000 Open source Revenue: 1134114000 Open source
20132013-12-31	Net margin	16.3%	Net Income: 252895000 Open source Revenue: 1551346000 Open source
20142014-12-31	Net margin	29.4%	Net Income: 657000000 Open source Revenue: 2234000000 Open source
20152015-12-31	Net margin	5.5%	Net Income: 144400000 Open source Revenue: 2604000000 Open source
20162016-12-31	Net margin	13%	Net Income: 399400000 Open source Revenue: 3084100000 Open source
20172017-12-31	Net margin	12.5%	Net Income: 443300000 Open source Revenue: 3551100000 Open source
20182018-12-31	Net margin	1.9%	Net Income: 77600000 Open source Revenue: 4131200000 Open source
20192019-12-31	Net margin	48.2%	Net Income: 2404300000 Open source Revenue: 4991100000 Open source
20202020-12-31	Net margin	9.9%	Net Income: 603400000 Open source Revenue: 6069900000 Open source
20112011-12-31	Free cash flow margin	31.7%	Revenue: 783431000 Open source Operating Cash Flow: 270084000 Open source Capital Expenditure: 21982000 Open source
20122012-12-31	Free cash flow margin	34.3%	Revenue: 1134114000 Open source Operating Cash Flow: 410613000 Open source Capital Expenditure: 21846000 Open source
20132013-12-31	Free cash flow margin	30.2%	Revenue: 1551346000 Open source Operating Cash Flow: 497349000 Open source Capital Expenditure: 29329000 Open source
20142014-12-31	Free cash flow margin	22.5%	Revenue: 2234000000 Open source Operating Cash Flow: 640000000 Open source Capital Expenditure: 137000000 Open source
20152015-12-31	Free cash flow margin	14.9%	Revenue: 2604000000 Open source Operating Cash Flow: 675200000 Open source Capital Expenditure: 286300000 Open source
20162016-12-31	Free cash flow margin	24.4%	Revenue: 3084100000 Open source Operating Cash Flow: 1086300000 Open source Capital Expenditure: 332700000 Open source
20172017-12-31	Free cash flow margin	21.4%	Revenue: 3551100000 Open source Operating Cash Flow: 1115600000 Open source Capital Expenditure: 357300000 Open source
20182018-12-31	Free cash flow margin	5.2%	Revenue: 4131200000 Open source Operating Cash Flow: 426000000 Open source Capital Expenditure: 213000000 Open source
20192019-12-31	Free cash flow margin	38.7%	Revenue: 4991100000 Open source Operating Cash Flow: 2084900000 Open source Capital Expenditure: 154700000 Open source
20202020-12-31	Free cash flow margin	47.7%	Revenue: 6069900000 Open source Operating Cash Flow: 3002900000 Open source Capital Expenditure: 106700000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 3B 2020

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20112011-12-31	Operating cash flow	270084000	Operating Cash Flow: 270084000 Open source
20122012-12-31	Operating cash flow	410613000	Operating Cash Flow: 410613000 Open source
20132013-12-31	Operating cash flow	497349000	Operating Cash Flow: 497349000 Open source
20142014-12-31	Operating cash flow	640000000	Operating Cash Flow: 640000000 Open source
20152015-12-31	Operating cash flow	675200000	Operating Cash Flow: 675200000 Open source
20162016-12-31	Operating cash flow	1086300000	Operating Cash Flow: 1086300000 Open source
20172017-12-31	Operating cash flow	1115600000	Operating Cash Flow: 1115600000 Open source
20182018-12-31	Operating cash flow	426000000	Operating Cash Flow: 426000000 Open source
20192019-12-31	Operating cash flow	2084900000	Operating Cash Flow: 2084900000 Open source
20202020-12-31	Operating cash flow	3002900000	Operating Cash Flow: 3002900000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 2.9B 2020

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20112011-12-31	Free cash flow	248102000	Operating Cash Flow: 270084000 Open source Capital Expenditure: 21982000 Open source
20122012-12-31	Free cash flow	388767000	Operating Cash Flow: 410613000 Open source Capital Expenditure: 21846000 Open source
20132013-12-31	Free cash flow	468020000	Operating Cash Flow: 497349000 Open source Capital Expenditure: 29329000 Open source
20142014-12-31	Free cash flow	503000000	Operating Cash Flow: 640000000 Open source Capital Expenditure: 137000000 Open source
20152015-12-31	Free cash flow	388900000	Operating Cash Flow: 675200000 Open source Capital Expenditure: 286300000 Open source
20162016-12-31	Free cash flow	753600000	Operating Cash Flow: 1086300000 Open source Capital Expenditure: 332700000 Open source
20172017-12-31	Free cash flow	758300000	Operating Cash Flow: 1115600000 Open source Capital Expenditure: 357300000 Open source
20182018-12-31	Free cash flow	213000000	Operating Cash Flow: 426000000 Open source Capital Expenditure: 213000000 Open source
20192019-12-31	Free cash flow	1930200000	Operating Cash Flow: 2084900000 Open source Capital Expenditure: 154700000 Open source
20202020-12-31	Free cash flow	2896200000	Operating Cash Flow: 3002900000 Open source Capital Expenditure: 106700000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

35.6% 2020

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Liabilities / assets	18.7%	Total Liabilities: 260259000 Open source Total Assets: 1394751000 Open source
20122012-12-31	Liabilities / assets	24.6%	Total Liabilities: 642710000 Open source Total Assets: 2613560000 Open source
20132013-12-31	Liabilities / assets	28.2%	Total Liabilities: 935617000 Open source Total Assets: 3317696000 Open source
20142014-12-31	Liabilities / assets	21.4%	Total Liabilities: 899944000 Open source Total Assets: 4201962000 Open source
20152015-12-31	Liabilities / assets	36.9%	Total Liabilities: 4838000000 Open source Total Assets: 13097000000 Open source
20162016-12-31	Liabilities / assets	34.4%	Total Liabilities: 4559500000 Open source Total Assets: 13253300000 Open source
20172017-12-31	Liabilities / assets	34.5%	Total Liabilities: 4690200000 Open source Total Assets: 13583300000 Open source
20182018-12-31	Liabilities / assets	34.2%	Total Liabilities: 4766600000 Open source Total Assets: 13931900000 Open source
20192019-12-31	Liabilities / assets	35.8%	Total Liabilities: 6272800000 Open source Total Assets: 17544600000 Open source
20202020-12-31	Liabilities / assets	35.6%	Total Liabilities: 6451800000 Open source Total Assets: 18103000000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.59× 2020

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20112011-12-31	Current assets / current liabilities	4.13×	Current Assets: 941270000 Open source Current Liabilities: 227785000 Open source
20122012-12-31	Current assets / current liabilities	4.15×	Current Assets: 1495600000 Open source Current Liabilities: 360089000 Open source
20132013-12-31	Current assets / current liabilities	3.75×	Current Assets: 2186857000 Open source Current Liabilities: 582429000 Open source
20142014-12-31	Current assets / current liabilities	4.61×	Current Assets: 2796029000 Open source Current Liabilities: 606740000 Open source
20152015-12-31	Current assets / current liabilities	3.41×	Current Assets: 2416000000 Open source Current Liabilities: 709000000 Open source
20162016-12-31	Current assets / current liabilities	3.13×	Current Assets: 2578200000 Open source Current Liabilities: 822900000 Open source
20172017-12-31	Current assets / current liabilities	3.1×	Current Assets: 2953900000 Open source Current Liabilities: 952500000 Open source
20182018-12-31	Current assets / current liabilities	2.88×	Current Assets: 3385000000 Open source Current Liabilities: 1174000000 Open source
20192019-12-31	Current assets / current liabilities	4.25×	Current Assets: 5076400000 Open source Current Liabilities: 1194300000 Open source
20202020-12-31	Current assets / current liabilities	3.59×	Current Assets: 5833000000 Open source Current Liabilities: 1624700000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2011 2011-01-01 – 2011-12-31	USD 175.32 million Exact value Exact value: 175315000 USD 2011-01-01 – 2011-12-31: 175315000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALEXION PHARMACEUTICALS, INC. · 2011-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Net Income: 175315000 USD Concept: fundies:NetIncome Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ANetIncome&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:NetIncome: 175315000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986614000034/alxn-20131231.xml#1463494 Filing: 000089986614000034 The citation records this snapshot. The page link may show a newer release later.	USD 270.08 million Exact value Exact value: 270084000 USD 2011-01-01 – 2011-12-31: 270084000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALEXION PHARMACEUTICALS, INC. · 2011-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Operating Cash Flow: 270084000 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 270084000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986614000034/alxn-20131231.xml#1462700 Filing: 000089986614000034 The citation records this snapshot. The page link may show a newer release later.	USD 21.98 million Exact value Exact value: 21982000 USD 2011-01-01 – 2011-12-31: 21982000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALEXION PHARMACEUTICALS, INC. · 2011-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Capital Expenditure: 21982000 USD Concept: fundies:CapitalExpenditure Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ACapitalExpenditure&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21982000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986614000034/alxn-20131231.xml#1716789 Filing: 000089986614000034 The citation records this snapshot. The page link may show a newer release later.	USD 248.1 million Calculation and evidence 270084000 − 21982000 USD Exact free cash flow: 248102000 USD 2011-01-01 – 2011-12-31: 270084000 USD · Inspect Operating Cash Flow · Source 2011-01-01 – 2011-12-31: 21982000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALEXION PHARMACEUTICALS, INC. · 2011-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Free cash flow: 248102000 USD Concept: free-cash-flow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 270084000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986614000034/alxn-20131231.xml#1462700 Filing: 000089986614000034 Input fundies:CapitalExpenditure: 21982000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986614000034/alxn-20131231.xml#1716789 Filing: 000089986614000034 The citation records this snapshot. The page link may show a newer release later.
2012 2012-01-01 – 2012-12-31	USD 254.82 million Exact value Exact value: 254822000 USD 2012-01-01 – 2012-12-31: 254822000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALEXION PHARMACEUTICALS, INC. · 2012-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Net Income: 254822000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: 254822000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986615000016/alxn-20141231.xml#602841 Filing: 000089986615000016 The citation records this snapshot. The page link may show a newer release later.	USD 410.61 million Exact value Exact value: 410613000 USD 2012-01-01 – 2012-12-31: 410613000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALEXION PHARMACEUTICALS, INC. · 2012-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Operating Cash Flow: 410613000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 410613000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986615000016/alxn-20141231.xml#602205 Filing: 000089986615000016 The citation records this snapshot. The page link may show a newer release later.	USD 21.85 million Exact value Exact value: 21846000 USD 2012-01-01 – 2012-12-31: 21846000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALEXION PHARMACEUTICALS, INC. · 2012-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Capital Expenditure: 21846000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 21846000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986615000016/alxn-20141231.xml#649063 Filing: 000089986615000016 The citation records this snapshot. The page link may show a newer release later.	USD 388.77 million Calculation and evidence 410613000 − 21846000 USD Exact free cash flow: 388767000 USD 2012-01-01 – 2012-12-31: 410613000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 21846000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALEXION PHARMACEUTICALS, INC. · 2012-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Free cash flow: 388767000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 410613000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986615000016/alxn-20141231.xml#602205 Filing: 000089986615000016 Input fundies:CapitalExpenditure: 21846000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986615000016/alxn-20141231.xml#649063 Filing: 000089986615000016 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	USD 252.9 million Exact value Exact value: 252895000 USD 2013-01-01 – 2013-12-31: 252895000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALEXION PHARMACEUTICALS, INC. · 2013-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Net Income: 252895000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: 252895000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986617000012/alxn-20151231.xml#604566 Filing: 000089986617000012 The citation records this snapshot. The page link may show a newer release later.	USD 497.35 million Exact value Exact value: 497349000 USD 2013-01-01 – 2013-12-31: 497349000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALEXION PHARMACEUTICALS, INC. · 2013-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Operating Cash Flow: 497349000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 497349000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986617000012/alxn-20151231.xml#603930 Filing: 000089986617000012 The citation records this snapshot. The page link may show a newer release later.	USD 29.33 million Exact value Exact value: 29329000 USD 2013-01-01 – 2013-12-31: 29329000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALEXION PHARMACEUTICALS, INC. · 2013-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Capital Expenditure: 29329000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 29329000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986617000012/alxn-20151231.xml#654105 Filing: 000089986617000012 The citation records this snapshot. The page link may show a newer release later.	USD 468.02 million Calculation and evidence 497349000 − 29329000 USD Exact free cash flow: 468020000 USD 2013-01-01 – 2013-12-31: 497349000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 29329000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALEXION PHARMACEUTICALS, INC. · 2013-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Free cash flow: 468020000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 497349000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986617000012/alxn-20151231.xml#603930 Filing: 000089986617000012 Input fundies:CapitalExpenditure: 29329000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986617000012/alxn-20151231.xml#654105 Filing: 000089986617000012 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	USD 657 million Exact value Exact value: 657000000 USD 2014-01-01 – 2014-12-31: 657000000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALEXION PHARMACEUTICALS, INC. · 2014-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Net Income: 657000000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: 657000000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986617000044/alxn-20161231.xml#603259 Filing: 000089986617000044 The citation records this snapshot. The page link may show a newer release later.	USD 640 million Exact value Exact value: 640000000 USD 2014-01-01 – 2014-12-31: 640000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALEXION PHARMACEUTICALS, INC. · 2014-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Operating Cash Flow: 640000000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 640000000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986617000044/alxn-20161231.xml#602622 Filing: 000089986617000044 The citation records this snapshot. The page link may show a newer release later.	USD 137 million Exact value Exact value: 137000000 USD 2014-01-01 – 2014-12-31: 137000000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALEXION PHARMACEUTICALS, INC. · 2014-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Capital Expenditure: 137000000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 137000000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986617000044/alxn-20161231.xml#652575 Filing: 000089986617000044 The citation records this snapshot. The page link may show a newer release later.	USD 503 million Calculation and evidence 640000000 − 137000000 USD Exact free cash flow: 503000000 USD 2014-01-01 – 2014-12-31: 640000000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 137000000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALEXION PHARMACEUTICALS, INC. · 2014-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Free cash flow: 503000000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 640000000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986617000044/alxn-20161231.xml#602622 Filing: 000089986617000044 Input fundies:CapitalExpenditure: 137000000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986617000044/alxn-20161231.xml#652575 Filing: 000089986617000044 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	USD 144.4 million Exact value Exact value: 144400000 USD 2015-01-01 – 2015-12-31: 144400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALEXION PHARMACEUTICALS, INC. · 2015-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Net Income: 144400000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: 144400000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986618000022/alxn-20171231.xml#704977 Filing: 000089986618000022 The citation records this snapshot. The page link may show a newer release later.	USD 675.2 million Exact value Exact value: 675200000 USD 2015-01-01 – 2015-12-31: 675200000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALEXION PHARMACEUTICALS, INC. · 2015-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Operating Cash Flow: 675200000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 675200000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986618000022/alxn-20171231.xml#704339 Filing: 000089986618000022 The citation records this snapshot. The page link may show a newer release later.	USD 286.3 million Exact value Exact value: 286300000 USD 2015-01-01 – 2015-12-31: 286300000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALEXION PHARMACEUTICALS, INC. · 2015-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Capital Expenditure: 286300000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 286300000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986618000022/alxn-20171231.xml#749370 Filing: 000089986618000022 The citation records this snapshot. The page link may show a newer release later.	USD 388.9 million Calculation and evidence 675200000 − 286300000 USD Exact free cash flow: 388900000 USD 2015-01-01 – 2015-12-31: 675200000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 286300000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALEXION PHARMACEUTICALS, INC. · 2015-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Free cash flow: 388900000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 675200000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986618000022/alxn-20171231.xml#704339 Filing: 000089986618000022 Input fundies:CapitalExpenditure: 286300000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986618000022/alxn-20171231.xml#749370 Filing: 000089986618000022 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	USD 399.4 million Exact value Exact value: 399400000 USD 2016-01-01 – 2016-12-31: 399400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALEXION PHARMACEUTICALS, INC. · 2016-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Net Income: 399400000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: 399400000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986619000010/alxn-20181231.xml#721290 Filing: 000089986619000010 The citation records this snapshot. The page link may show a newer release later.	USD 1.09 billion Exact value Exact value: 1086300000 USD 2016-01-01 – 2016-12-31: 1086300000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALEXION PHARMACEUTICALS, INC. · 2016-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Operating Cash Flow: 1086300000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1086300000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986619000010/alxn-20181231.xml#720652 Filing: 000089986619000010 The citation records this snapshot. The page link may show a newer release later.	USD 332.7 million Exact value Exact value: 332700000 USD 2016-01-01 – 2016-12-31: 332700000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALEXION PHARMACEUTICALS, INC. · 2016-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Capital Expenditure: 332700000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 332700000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986619000010/alxn-20181231.xml#767664 Filing: 000089986619000010 The citation records this snapshot. The page link may show a newer release later.	USD 753.6 million Calculation and evidence 1086300000 − 332700000 USD Exact free cash flow: 753600000 USD 2016-01-01 – 2016-12-31: 1086300000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 332700000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALEXION PHARMACEUTICALS, INC. · 2016-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Free cash flow: 753600000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1086300000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986619000010/alxn-20181231.xml#720652 Filing: 000089986619000010 Input fundies:CapitalExpenditure: 332700000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986619000010/alxn-20181231.xml#767664 Filing: 000089986619000010 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	USD 443.3 million Exact value Exact value: 443300000 USD 2017-01-01 – 2017-12-31: 443300000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALEXION PHARMACEUTICALS, INC. · 2017-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Net Income: 443300000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: 443300000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986620000012/alxn10k12312019.htm#2730930 Filing: 000089986620000012 The citation records this snapshot. The page link may show a newer release later.	USD 1.12 billion Exact value Exact value: 1115600000 USD 2017-01-01 – 2017-12-31: 1115600000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALEXION PHARMACEUTICALS, INC. · 2017-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Operating Cash Flow: 1115600000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1115600000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986620000012/alxn10k12312019.htm#2461771 Filing: 000089986620000012 The citation records this snapshot. The page link may show a newer release later.	USD 357.3 million Exact value Exact value: 357300000 USD 2017-01-01 – 2017-12-31: 357300000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALEXION PHARMACEUTICALS, INC. · 2017-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Capital Expenditure: 357300000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 357300000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986620000012/alxn10k12312019.htm#2477826 Filing: 000089986620000012 The citation records this snapshot. The page link may show a newer release later.	USD 758.3 million Calculation and evidence 1115600000 − 357300000 USD Exact free cash flow: 758300000 USD 2017-01-01 – 2017-12-31: 1115600000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 357300000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALEXION PHARMACEUTICALS, INC. · 2017-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Free cash flow: 758300000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1115600000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986620000012/alxn10k12312019.htm#2461771 Filing: 000089986620000012 Input fundies:CapitalExpenditure: 357300000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986620000012/alxn10k12312019.htm#2477826 Filing: 000089986620000012 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	USD 77.6 million Exact value Exact value: 77600000 USD 2018-01-01 – 2018-12-31: 77600000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALEXION PHARMACEUTICALS, INC. · 2018-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Net Income: 77600000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: 77600000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2619832 Filing: 000089986621000014 The citation records this snapshot. The page link may show a newer release later.	USD 426 million Exact value Exact value: 426000000 USD 2018-01-01 – 2018-12-31: 426000000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALEXION PHARMACEUTICALS, INC. · 2018-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Operating Cash Flow: 426000000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 426000000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2312130 Filing: 000089986621000014 The citation records this snapshot. The page link may show a newer release later.	USD 213 million Exact value Exact value: 213000000 USD 2018-01-01 – 2018-12-31: 213000000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALEXION PHARMACEUTICALS, INC. · 2018-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Capital Expenditure: 213000000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 213000000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2327645 Filing: 000089986621000014 The citation records this snapshot. The page link may show a newer release later.	USD 213 million Calculation and evidence 426000000 − 213000000 USD Exact free cash flow: 213000000 USD 2018-01-01 – 2018-12-31: 426000000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 213000000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALEXION PHARMACEUTICALS, INC. · 2018-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Free cash flow: 213000000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 426000000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2312130 Filing: 000089986621000014 Input fundies:CapitalExpenditure: 213000000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2327645 Filing: 000089986621000014 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	USD 2.4 billion Exact value Exact value: 2404300000 USD 2019-01-01 – 2019-12-31: 2404300000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALEXION PHARMACEUTICALS, INC. · 2019-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Net Income: 2404300000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: 2404300000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2618757 Filing: 000089986621000014 The citation records this snapshot. The page link may show a newer release later.	USD 2.08 billion Exact value Exact value: 2084900000 USD 2019-01-01 – 2019-12-31: 2084900000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALEXION PHARMACEUTICALS, INC. · 2019-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Operating Cash Flow: 2084900000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 2084900000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2311155 Filing: 000089986621000014 The citation records this snapshot. The page link may show a newer release later.	USD 154.7 million Exact value Exact value: 154700000 USD 2019-01-01 – 2019-12-31: 154700000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALEXION PHARMACEUTICALS, INC. · 2019-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Capital Expenditure: 154700000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 154700000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2326761 Filing: 000089986621000014 The citation records this snapshot. The page link may show a newer release later.	USD 1.93 billion Calculation and evidence 2084900000 − 154700000 USD Exact free cash flow: 1930200000 USD 2019-01-01 – 2019-12-31: 2084900000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 154700000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALEXION PHARMACEUTICALS, INC. · 2019-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Free cash flow: 1930200000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 2084900000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2311155 Filing: 000089986621000014 Input fundies:CapitalExpenditure: 154700000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2326761 Filing: 000089986621000014 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	USD 603.4 million Exact value Exact value: 603400000 USD 2020-01-01 – 2020-12-31: 603400000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALEXION PHARMACEUTICALS, INC. · 2020-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Net Income: 603400000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 603400000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2617686 Filing: 000089986621000014 The citation records this snapshot. The page link may show a newer release later.	USD 3 billion Exact value Exact value: 3002900000 USD 2020-01-01 – 2020-12-31: 3002900000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALEXION PHARMACEUTICALS, INC. · 2020-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Operating Cash Flow: 3002900000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 3002900000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2310155 Filing: 000089986621000014 The citation records this snapshot. The page link may show a newer release later.	USD 106.7 million Exact value Exact value: 106700000 USD 2020-01-01 – 2020-12-31: 106700000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALEXION PHARMACEUTICALS, INC. · 2020-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Capital Expenditure: 106700000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 106700000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2325852 Filing: 000089986621000014 The citation records this snapshot. The page link may show a newer release later.	USD 2.9 billion Calculation and evidence 3002900000 − 106700000 USD Exact free cash flow: 2896200000 USD 2020-01-01 – 2020-12-31: 3002900000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 106700000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALEXION PHARMACEUTICALS, INC. · 2020-12-31 ALEXION PHARMACEUTICALS, INC. (edgar:899866) Free cash flow: 2896200000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T11:22:49Z Snapshot: 8b8a3a5d4e31e0dfd99b108e539dbf7ab7a42363b61f2062a453ef3e38db973b Dimensions: Consolidated View: https://fundies.io/companies/edgar/899866?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 3002900000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2310155 Filing: 000089986621000014 Input fundies:CapitalExpenditure: 106700000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/899866/000089986621000014/alxn-20201231.htm#2325852 Filing: 000089986621000014 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

225 filings · 6,367 latest values · 6,367 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000899866, 899866, ALXN, edgar:899866

Also known as ALEXION PHARMACEUTICALS INC, ALEXION PHARMACEUTICALS, INC., Alexion Pharmaceuticals, Inc.

ALEXION PHARMACEUTICALS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2020 2020-01-01 – 2020-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation